VEGFA and non-small cell lung carcinoma: The addition of avastin to atezolizumab and platinum-based chemotherapy offered a prolongation of OS from 14.7 months to 19.2 months (IMpower 150 trial), which led to the incorporation of anti-VEGF treatment in the first-line setting of NSCLC [39].